Key facts
- It has raised $7.0M across 2 recorded rounds; the latest was Seed Round ($250K) in May 2024.
- Notable investors include CONNECT (San Diego), National Cancer Institute, NuFund Venture Group, TL Foundation.
- Resolute Science has filed 3 Form Ds with the SEC since 2024, most recently Apr 2026 ($2.9M sold to 25 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Resolute Science
Funding rounds
2 roundsAbout Resolute Science
Developer of targeted cancer therapeutics designed for the treatment of aggressive solid tumors. The company's platform develops synthetic drug conjugates using a macrophage-targeted delivery approach that leverages tumor-associated macrophages to process and distribute cytotoxic or radiotherapeutic payloads within tumors, supports a pipeline of preclinical drug candidates, enabling healthcare professionals to overcome resistance mechanisms and improve treatment options for patients with hard-to-treat cancers.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2020
- Employees
- 8
- Website
- resolutescience.com/
- Ownership
- Privately Held (backing)
Resolute Science doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Resolute Science shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Resolute Science in its N-PORT filings yet. We sweep new filings monthly.